MedTrace Logo

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

NCT00765700 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 364

Last updated 2013-09-27

No results posted yet for this study

Summary

Imprimis Pharmaceuticals is investigating a proprietary, topical cream formulation consisting of 10% ketoprofen (containing 100 mg of ketoprofen in 1gram of cream) for the local treatment of acute musculoskeletal pain.

Conditions

  • Sprain
  • Strain
  • Acute Soft Tissue Injury

Interventions

DRUG

Topical Ketoprofen 10% Cream

Topical Administration

DRUG

Topical Placebo Cream

Topical Administration

Sponsors & Collaborators

  • Cato Research

    collaborator INDUSTRY

  • Imprimis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Illana Katsnelson, MD · Cato Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765700 on ClinicalTrials.gov